{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:59:10Z","timestamp":1790985550861,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/cad.0b013e328363ccbb","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T07:22:16Z","timestamp":1373959336000},"page":"975-979","source":"Crossref","is-referenced-by-count":1,"title":["Bevacizumab in advanced breast cancer"],"prefix":"10.1097","volume":"24","author":[{"given":"Juan De la","family":"Haba-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Rodr\u00edguez-Lescure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cortijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Guirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Torrej\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210203","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/annonc\/mdq774","article-title":"European cancer mortality predictions for the year 2011.","volume":"22","author":"Malvezzi","year":"2011","journal-title":"Ann Oncol"},{"key":"R3-12-20210203","first-page":"721","article-title":".Survival in cancer of the breast in Zaragoza (1960-1990) in relation to age, clinical stage and period of time of the diagnosis.","volume":"105","author":"Navarro Garcia","year":"1995","journal-title":"Med Clin (Barc)"},{"key":"R4-12-20210203","first-page":"605","article-title":"Trends in cancer mortality in Catalonia (1975-1998).","volume":"116","author":"Fernandez","year":"2001","journal-title":"Med Clin (Barc)"},{"key":"R5-12-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/ctrv.1999.0161","article-title":"Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer.","volume":"26","author":"Stockler","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"R6-12-20210203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1634\/theoncologist.6-2-133","article-title":"Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.","volume":"6","author":"Esteva","year":"2001","journal-title":"Oncologist"},{"key":"R7-12-20210203","first-page":"1760","article-title":"Chemotherapy: what progress in the last 5 yearsJ Clin O","volume":"23","author":"Hamilton","year":"2005","journal-title":"ncol"},{"key":"R8-12-20210203","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1158\/1078-0432.CCR-08-0593","article-title":".VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.","volume":"14","author":"Burstein","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R9-12-20210203","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":".Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-12-20210203","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":".Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"R11-12-20210203","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","article-title":".RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"R12-12-20210203","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.2174\/092986711797636072","article-title":".The role of antiangiogenetic agents in the treatment of breast cancer.","volume":"18","author":"Bareschino","year":"2011","journal-title":"Curr Med Chem"},{"key":"R14-12-20210203","first-page":"CD003368","article-title":"Addition of drugs to a chemotherapy regimen for metastatic breast cancer.","volume":"3","author":"Jones","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-12-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-007-9550-7","article-title":".Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.","volume":"107","author":"Dufresne","year":"2008","journal-title":"Breast Cancer Res Treat"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e328363ccbb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:58:01Z","timestamp":1786039081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201310000-00012"}},"subtitle":["a new model for the assessment of activity in non-first-line treatment regimens"],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e328363ccbb","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}